---
title: test 2
slug: test-2
createdAt: 2020-03-26T03:20:50.000Z
---

Infinity embed:

\<iframe src="https\://app.startinfinity.com/b/oXsPbriiano" width="100%" height="600" style="border: 0; box-shadow: 5px 5px 56px 0px rgba(0,0,0,0.25);">\</iframe>



[https://app.startinfinity.com/b/oXsPbriiano](https://app.startinfinity.com/b/oXsPbriiano)



\<iframe class="stackby-embed" src="https\://stackby.com/embed/shr52hTjNEll4y6EY8g" frameborder="0" width="100%" height="2000" >\</iframe>







:::Iframe{code="<!-- <p>paste iframe code here</p> --><iframe class=&#x22;stackby-embed&#x22; src=&#x22;https://stackby.com/embed/shr52hTjNEll4y6EY8g&#x22; frameborder=&#x22;0&#x22; width=&#x22;100%&#x22; height=&#x22;2000&#x22; ></iframe>" iframeHeight="0"}

:::





:::Iframe{code="<!-- <p>paste iframe code here</p> --><iframe src=&#x22;https://app.startinfinity.com/b/oXsPbriiano&#x22; width=&#x22;100%&#x22; height=&#x22;600&#x22; style=&#x22;border: 0; box-shadow: 5px 5px 56px 0px rgba(0,0,0,0.25);&#x22;></iframe>" iframeHeight="0"}

:::

\<iframe src="https\://app.startinfinity.com/b/oXsPbriiano" width="100%" height="600" style="border: 0; box-shadow: 5px 5px 56px 0px rgba(0,0,0,0.25);">\</iframe>





:::Iframe{code="<!-- <p>paste iframe code here</p> --><!-- START OF  HTTPS://HAPPYSCRIBE.CO EMBED CODE -->&#xA;<div id=&#x22;hs-embed-container&#x22; style='position:relative;display:flex;width:100%;height:600px;'>&#xA;<div id=&#x22;hs-embed-placeholder&#x22; style='position:absolute;top:0;bottom:0;left:0;right:0;margin:10px;overflow:auto;font-size: 14px !important'>&#xA;<h2><a title=&#x22;Geert Vanden Bossche & Peter McCullough Webinar Presentation by Peter McCullough.mp4 was transcribed from audio to text using Happy Scribe&#x22; style=&#x22;color: #3E3E3B !important;text-decoration: none !important;&#x22; target=&#x22;_blank&#x22; href=&#x22;https://www.happyscribe.com/?utm_source=embed-player&utm_term=fe190cef7d60476b9772881e3f626721&#x22;> Geert Vanden Bossche & Peter McCullough Webinar Presentation by Peter McCullough.mp4 - powered by Happy Scribe</a></h2>&#xA;<p>OK, I'm Dr. Peter McCulloh, and the opinions expressed are those of my own and not of my institutions, and I'm going to tackle the topic of the pathophysiological basis and clinical rationale for early ambulatory treatment of sars-cov-2 or covid-19 that we just heard from Dr. VandenBosch that in a sense, this is a war on many of the points he made is that the virus really is winning. And if this is a war and we're going to follow this analogy, this talk is really about how to handle the casualties that we're in a mass casualty situation.</p><p>We're in a war. We keep trying to make tactical moves. But as the data are bearing out, as the science bears out, our tactical moves may be working against us. So how can we deal with the mass casualties that have come in so far and those that we anticipate? Next slide. I saw this coming in March and April, and I'm a cardiologist and internist and epidemiologist. I'm an academic medicine. I'm the editor of two major journals.</p><p>I have been very involved in drug development and have been on day safety monitoring boards for the National Institutes of Health and pharmaceutical industries. And when this happened, I turn my academic career on a dime and put all my efforts into covid-19 I saw this as the challenge of my career is the challenge of most physicians career. And I wasn't going to sit on the sidelines and I certainly wasn't going to be a detractor. I wanted to be a leader and face this epidemic full on.</p><p>And I put together a team of top US academicians, some from India, many from Italy. And we surveyed the literature through May and June and July. First, we submitted our findings to the American Journal of Medicine in this paper, titled The Pathophysiology Basis and Rationale for Early Outpatient Treatment of sars-cov-2 was published in the American Journal of Medicine. I can tell you when we submitted this paper, there were fifty thousand papers in the literature, some of which Dr.</p><p>VandenBosch cited. They had to deal with a pathophysiology or epidemiology or virology, but there wasn't a single paper that actually outlined a treatment approach and the rationale for a treatment approach. And we recognized that Dr. Vladimir Zelenko and George Friedman, Brian Tyson and Stella Emanuel and many others had already started to innovate in their practices. And we saw these trends starting to emerge in the literature. So we put these concepts together. And our major focus here was the following.</p><p>We knew this was a fatal virus. We knew it had to be treated early. There's not a single fatal infectious disease that we treat. It's just not a principle that would ever be acceptable in medicine. And we knew that because it's a viral infection that had many complicated features, we were going to need to use multiple drugs. We didn't think for a minute that a single drug was going to influence outcomes in this infection. So we looked in the literature for signals of benefit and acceptable safety as we assembled our treatment recommendations.</p><p>Next slide. The follow up paper was published in reviews in Cardiovascular Medicine, a dedicated issue to covid-19 that had its own issue editor. And this paper was a very heavily peer reviewed and thoroughly peer reviewed, even to a greater extent than usual papers submitted to this journal and in this paper. Now, I recruited fifty six other authors, and I particularly wanted more input from authors who are directly treating the virus and having success in reducing rates of hospitalization and death.</p><p>I want to doctors who had developed experience in multidrug therapy for covid-19 recognizing there wasn't a single randomized trial, not a single randomized trial that simultaneously addressed all the features of the infection, not a single one. So we couldn't rely on a clinical trial to give us guidance. We certainly couldn't rely on the agencies that rely on clinical trials such as the CDC or the NIH or the WHL. They're simply not going to move with the type of speed that we needed to move to handle this mass casualty situation.</p><p>So this paper titled Multifaceted, highly targeted, sequential multidrug treatment of early ambulatory, high risk sars-cov-2 infection became the state of the art for ambulatory outpatient treatment for covid-19. Now, both of these papers that I've shared with you are the most downloaded papers in those journals since the moment they were published. To give you any idea of the impact that these papers are having, they became the basis for the only early ambulatory treatment guide that is endorsed by a physician organization in America and its shared worldwide.</p><p>And so it's very, very important to those of you who are handling patients with covid-19 or have family members. And so all the principles outlined in the next few slides, next slide. It's important to understand that the principles that are outlined are are scalable and here is one of the leading covid front facing covid treatment centers in California, headed by Dr. Brian Tyson and his group. This group that you're looking at here has handled more than five thousand individuals with covid-19 that are high risk and very successfully managed to avoid hospitalization and virtually every one of them.</p><p>So compared to doing nothing, a group like this is powerful in changing some of the terrible statistics that we've seen in the epidemic, including hospitalizations and death and the proposal of doing nothing for patients and waiting for them to be hospitalized versus doing something early at home and having patients stay at home, not further contaminated or exposing other individuals. That proposal is not even a discussion from a medical ethics perspective or from a good clinical practice perspective. Physicians basically have divided in almost every country into those who treat early covid-19 and those who don't.</p><p>Even countries have divided. United States is kind of a divided country. So we have doctors who do and doctors who don't. There are other countries that absolutely do not, including Canada, Australia, UK, and then there's other countries who absolutely treat early all the time, including India, Pakistan, Russia, Turkey, most of Eastern Europe, many countries in South America. So you can see that our treatment response in in our countries and between countries is very different.</p><p>And that goes to that speaks to the the really the novelty of facing such a worldwide calamity. Next slide. Now, we knew at least by April or May that there were three major parts to this infection, the first was viral proliferation. And very early on, the virus does proliferate and there are early symptoms. Data are suggesting that there's less and less asymptomatic spread. In fact, people are suddenly symptomatic when they have a replication of their contagious and that this vibration phase can last about two weeks or so.</p><p>But it's most intense early and it becomes less over time. There is a cytokine injury or inflammation that occurs as shown in blue, and there's a real tremendous activation of interleukin six and a whole variety of other factors. Doctors will recognize the inflammatory signature, if you will, of the infection, including a high CRP value, a high interleukin six fire suppression of the lymphocyte count, a high dimer level. In fact, that Dimery level is a harbinger for thrombosis and the thrombosis is not the typical thrombosis we see.</p><p>It leads with what's called hemagglutinin. And as Dr. VandenBosch explained, the spike protein itself is truly pathogenic. It impales a cell surface proteins on red blood cells and platelets and participates in micro thrombosis. And it has been shown by many that in the fatal days of the syndrome, in fact, thrombosis is the heavily dominant process, micro thrombosis in the lungs, Mechel, thrombosis in large veins and in fact, fatal strokes and fatal myocardial infarction. And so the syndrome is complex.</p><p>Looking at the slide, you can see the mortality rate does creep up and becomes quite high at 30 days. But importantly, we have an opportunity here. This virus gives us an opportunity for treatment. It's a lot different than Ebola or some other viruses.</p><p>We didn't have it. We don't have much of a chance early on. We have two weeks to get organized and start treating this problem in order to reduce hospitalization and death. So our therapeutic response in the hospital too late, but in the outpatient arena, which can be early and very effective, involves the principles of applying intracellular anti-infectives and now antiviral antibodies. Corticosteroids are immunomodulators and then antiplatelet drugs and anticoagulants. Always, always three prongs.</p><p>So every time somebody wants to bring up an argument regarding one particular drug, let's say they want to talk about Bamma Live IMB or they want to talk about dexamethasone, I always say, you know what, it's fine to talk about these, but don't expect a single drug is a cure for this illness. We never thought that in HIV. We never thought that hepatitis C, we need to think about drugs, demonstrated clinical trials, signals of benefit, not superiority, not cures, but signals that benefit with acceptable safety to allow us to assemble them into a multi drug protocol.</p><p>Next slide. I've testified at the US Senate on November 19th, as well as the Texas Senate on March 10th, that there have always been four pillars to the pandemic response. As Dr. VandenBosch mentioned, we have had unprecedented efforts on contagion control to stop the spread. And remember, originally, the message on contagion control was to just slow down the infection. It wasn't meant to be curative. That was just to slow down the infection so we wouldn't overflow our hospitals.</p><p>And what Dr. VandenBosch has taught us is that contagion control may have backfired a little bit, meaning that in areas where there's very intense contagion control, there's evolutionary pressures for the virus to become more contagious. And in fact, that's what we've seen in the United States, the states that have had the strictest contagious control and lockdown, they've actually done worse with covid-19 at the same thing is true on a country wide basis. The country has had the most draconian lockdowns, have done the worst with covid-19 and the ones that have actually poor countries, countries where the population is more dense and people just can't do contagious control.</p><p>They've actually had an easier time with the pandemic. Now, some have said this is confounding by indication or cause and effect that when covid-19 is bad, you lock down more. But I think on average, my opinion is that lockdown's and contagion control has largely backfired. I've always said that we should take prudent measures, but very intensive things like testing and and testing asymptomatic people. A draconian lockdown's with triple masking things of this would just it just didn't make sense.</p><p>The virus is going to win. And I think he's right. The second pillar is early home treatment or ambulatory treatment. And the principle here is there's two bad outcomes with covid-19, there's hospitalization and death. Now, virtually all the deaths occur after long hospitalizations. So that means our only chance to reduce hospitalization and death meaningfully is to treat before the hospital. I think everybody would agree with that. If we don't have a laser focus on treating before, the hospital will never reduce mortality.</p><p>If we don't have regular features in virtually every media channel we can to educate our public on early treatment, we'll never reduce hospitalization and death. If we never give information to high risk individuals when we hand them a test result for covid-19, we'll never reduce hospitalization and death. You can see that the tone of this, the tone of this is we've had a complete and total blunder, a complete and total oblivion, a complete and total block on the opportunity for early ambulatory treatment to reduce the intensity and duration of symptoms, reduce the risks of hospitalization and death, and bring us through the pandemic.</p><p>Now, the third pillar of pandemic response is the hospital, and that's fine. The hospital is trying to provide supportive care. Twenty five percent of patients need to go on the mechanical ventilator. That's fine. The treatments in the hospital are modestly effective, also controversial, every single one of them. There are mixed data on every single approach in the.</p><p>Hospital, the hospital likes to stay, are very long, and virtually all the deaths occur in the hospital and the mortality rates acceptably high.</p><p>So I won't spend much more time on hospitalization. I think all the.</p><p>Action is avoiding the hospital to begin with, and the last pillar is vaccination or herd immunity. You've just heard probably the most expert person in the world on vaccine development, in virology and epidemiology. And what I've learned from Dr. VandenBosch is that vaccination, as as well intended as it is, in fact, may backfire on us because it creates a very monolithic immunity. That is the immunity really solely directed against the spiked protein or a vector that could carry that genetic code in some vaccines actually have no vector.</p><p>So there's no opportunity for vector immunity. It's a very monolithic immunity. It's transient and it is administered in patients where we can expect from the clinical trials to have a very minimal public health impacts. What do I mean by that? All the big major randomized trials of vaccines had attack rates, that is infection rates in both placebo and vaccine groups of less than one percent when observed over three months. So if the attack rates are less than one percent in the scientific studies, why would we expect anything different from vaccines?</p><p>We'll have about a less than one percent population benefit from vaccines. And in fact, what we may do is end up having a disaster, as Dr. VandenBosch has implied, meaning that the virus now will face a very monolithic group of individuals in terms of their immunity and quickly find out ways to mutate and scoot past these vaccines and potentially cause a more severe infection. So I've never been a proponent of mass vaccination. I've been open to selective vaccination as a strategy.</p><p>But now I'm deeply concerned with what I'm seeing. And then lastly on vaccine is we have upfront safety. So we know we have anaphylactic reactions that have been well described in the United States. We've had over 16 hundred vaccine related deaths reported to the CDC vaccine adverse event reporting system. These deaths recently has been released, have been reviewed by the CDC and FDA doctors, and they have opined that not a single death is related to the vaccine, although the deaths do seem to cluster around the first, second and third days of the vaccine.</p><p>We've also heard from experts, alarmingly, that only about 10 percent of adverse events that occurred in vaccines, including death, are probably reported in the database. Since there needs to be a surviving person to figure out how to enter that the CDC or contact the CDC. So there's great concern that, in fact, these early deaths could be related to the vaccine or at least are temporally related. And because of the other adverse events, platelet and red blood cell abnormalities, there are now nearly a dozen countries in Europe that have withdrawn the vaccine from the market.</p><p>So I think you're going to hear a lot more about vaccine and vaccine safety. We have yet to see any population impact in terms of efficacy. I anticipate from the attack rate concept that I've mentioned and from the concepts that Dr. VandenBosch is mentioned, I will make a prediction that the vaccine will not make a significant impact on the pandemic and and potentially could worsen it. Next slide. Now, here is the most widely cited figure probably right now in all of medicine, and this is called sequence multidrug therapy for early ambulatory covid-19 and I'll walk you through.</p><p>It's very important. The first principle up front is when someone develops the symptomatic syndrome of covid-19 not being antibody positive. I mean, being sick with the characteristic features of fever, nasal congestion, myalgia, difficulty breathing, et cetera, that we undergo some forms of reducing the acute infectivity of that individual, like having open the windows, having fresh air, reasonable measures not to spread it to others and then undergo risk stratification. And what I mean by that is individuals under age 50 without any other medical problems have a very low risk of death.</p><p>Is less than one percent in our group now in two separate papers is advising no treatment outside of some reasonable nutritional supplements, nutraceuticals that may provide some benefit. So outside of a nutraceutical bundle age under 50, no underlying medical problems, no treatment. That means for a lot of countries with very young populations, we don't have to be doing a lot of treatment in the United States. For most primary care practices, it means about two thirds of individuals will get no treatment for covid-19.</p><p>I personally think that's fine. Now, if patients present with severe symptoms at any age or over age 50 with medical problems, then sequence multidrug therapy is advised. The very first step, if available, is administration of monoclonal antibodies. There is a Liley and Regeneron products that can be administered. They are pre purchased by the government, at least in the United States. Make a phone call and they go into an infusion room in a hospital and get the antibodies.</p><p>I do rely on these. However, we've heard recent reports that, again, maybe these variants of the virus can escape the neutralizing effect of these monoclonal antibodies. And we're back to square one. I personally don't rely on the antibodies as a monotherapy, but I do try to use them up front if I can, as I get into sequence. Multi drug therapy beyond that. And that yellow box, the big yellow box is the intracellular anti-infectives. And there are a variety of approaches hydroxy chloroquine, ivermectin or favipiravir.</p><p>These are Aurel off target antivirals, probably favipiravir used in Japan, Russia, India, other countries is the most direct antiviral. It's an RNA dependent polymerase inhibitor. And then combined with either doxycycline or Zathura for two reasons, there is a small percentage of overlap with atypical organisms that these antibiotics treat. They also treat bacterial superinfection and they have some mild antiviral properties themselves. Now, on day five, if there's any pulmonary symptoms, we do advise corticosteroids doctors.</p><p>Jean-Pierre showed you the budesonide trial. There are also favorable data with dexamethasone and prednisone. Prednisone is our most commonly administered corticosteroid and most abundantly available. So five days forty milligrams with no taper is perfectly fine for prednisone. Budesonide nebulized is a terrific opportunity. And then very importantly, in that kind of steroid immune modulator boxes, colchicine. And what a lot of people don't realize is the largest, highest quality prospective randomized treatment trial in all of covid-19 is the Corona trial.</p><p>And that was with colchicine. It's colchicine zero point six milligrams twice a day for three days and then zero point six milligrams thereafter for thirty days. That's the most positive trial we have. Unfortunately, it was stopped administratively early for no real reason. But still, at forty one hundred individuals, there was a fifty fifty percent reduction in mortality and a significant reduction in hospitalization. That's the best trial we have. It kind of blows away any clinical trial we have with monoclonal antibodies.</p><p>Does a beer with dexamethasone or anything else. It's colchicine. So colchicine can be really front loaded as we start to work through sequence multidrug and used early on. I've relied on it ever since the Grecco nineteen trial that was published last summer by the Greeks. Beyond that, we have one final step to take care of, and that's anticoagulation now because the virus markedly up regulates smallpox and A2, which is a regulatory enzyme promoting platelet aggregation. We advise full dose aspirin, three hundred twenty five milligrams a day for the course of the illness and then for higher risk patients, heart and lung disease.</p><p>We go ahead and use subcutaneous enoxaparin or a novel anti-coagulant, a full dose. Now, people have asked, how long do you continue all these drugs? It's about four to six drugs. And the answer is for patients. Mild symptoms or a lesser comorbidities that can be short as five days, an average adult, it's about 10 days for seniors in senior facilities or other patients who are very frail. It can be as long as 30 days of treatment.</p><p>But sequence multidrug therapy is currently the state of the art right now. And I can tell you, compared to doing nothing, what you're seeing on this slide is highly effective. And my personal view is my moral and compassionate view is what you see on the slide should never be withheld from a sick patient who has covid-19 on the right hand side of the slide is oxygen support. Some patients do need oxygen support. It has been done safely in the home.</p><p>Recall that three quarters of patients who were hospitalized never need the mechanical ventilator. So if they don't need the mechanical ventilator, it means a lot of hospitalized patients could have been managed at home with even with very severe illness if we have supplemental oxygen and good telemedicine observation. Next slide. Well, what are the results, John mentioned Vladimir Salenko, who is the very first innovator. He's the senior author on our updated paper. Another innovator was Brian Proctor in Texas.</p><p>This paper now has been fully peer reviewed and is in the publication process, will be cited in PubMed. But what Dr Proctor has shown in a high risk cohort of nearly nine hundred covid positive ambulatory patients, that compared to expected and we have very good calculators of untreated event rates in terms of mortality and hospitalization from the Cleveland Clinic compared to the projected rates. You can see that sequence. Multidrug therapy is associated with about an eighty five percent reduction in hospitalization and death.</p><p>So even if you argue that selection bias is playing a role in amplifying perceived efficacy, it's still highly significant. I would take honestly, I would take a 15 percent relative risk reduction in hospitalization and death.</p><p>Oral therapy as an outpatient, now even enhanced with our antibodies, blows away therapeutic nihilism. The next time a doctor ever tries to advise therapeutic nihilism or a patient ever thinks they should accept it, there should be an immediate full stop. There's been some terrible thinking that has crept into the mind sets of doctors, patients, media representatives, etc.. What you're seeing on this slide ought to be the biggest story that the major media could ever play. This is the biggest story.</p><p>This is bigger than any vaccine announcement. This is bigger than any news piece on wearing a mask or social distancing sequence, oral multidrug therapy. Eighty five percent reduction in hospitalizations and death. And it delivers patients to the other side of the illness. And as Dr. VandenBosch implied, the other side of the illness is a more complete and durable immunity, both antibody based and not non antibody based. And as Dr. VandenBosch and John peer reviewed, although it's theoretically possible that could be a serious infection, we are down to fewer than one hundred cases reported in the literature out of one hundred and ten million overall cases where it could be a second infection.</p><p>I've looked at every one of them carefully. I think in virtually every case it's a mis interpretation of a nasal PCR test. In fact, the patients only had one clinical infection. Can people have subclinical infections, have low level of antibodies and then have the real clinical syndrome later on? Sure, that's been well described, but I'm very certain for the vast majority of us, no matter what variant or strain we've had, it's one infection per person and then we're done with it.</p><p>And that the clinical syndrome yields durable, complete immunity and that can't be improved upon. And under no circumstances should I covered recovered patient undergo vaccination because it can offer no opportunity for benefit. It can only offer harm. These patients were strictly excluded from the clinical trials by the US, FDA and the manufacturers, and it should not happen.</p><p>This is a very, very important message. covid recovered patients under no circumstances should undergo vaccination. Next slide. So to finish and conclude covid-19 pandemic is a global disaster, we're in the business of handling mass casualties, the pathophysiology is complex. It's not amenable to a single drug. So the next person who tries to claim that a drug is a miracle drug, I really think they're doing a disservice to the clinical and research community. Despite contagion control efforts, the outbreak is worsening with two poor outcomes hospitalization and death and potentially contagious control is backfiring, and that only reasonable and prudent measures without lockdown or other more drastic measures should have been the better approach.</p><p>Hospitalization and late treatment form an inadequate safety net for patients. The hospitalization is not saving. All the patient's mortality rate is unacceptably high. Early ambulatory therapy, with sequence multidrug regimens supported by available sources of evidence, have a positive benefit to risk ratio. They reduce risk of hospitalization and death. They more safely temporize in order to help us close the crisis, potentially with a vaccination or probably more completely with natural immunity. So I'll stop here and open it up for our next segment of dialog.</p>&#xA;</div>&#xA;<div class='hs-embed' data-id='fe190cef7d60476b9772881e3f626721'></div>&#xA;<script>&#xA;var js=document.createElement('script');js.type='text/javascript';js.async=true;js.src='https://embed.happyscribe.co/main.js';document.head.appendChild(js);&#xA;</script>&#xA;</div>&#xA;<!-- END OF HTTPS://HAPPYSCRIBE.CO EMBED CODE -->" iframeHeight="1500"}

:::













